A Study by FMUC proposes an alternative approach to the treatment of Paediatric Multiple Sclerosis
A Study by FMUC Proposes an Alternative Approach to the Treatment of Paediatric Multiple Sclerosis
A study conducted by Filipe Paiva -─ researcher, PhD student and faculty member at the Faculty of Medicine of the University of Coimbra -─ has concluded that the medicine Natalizumab (Tysabri®) may be a more assertive and effective approach in the treatment of paediatric multiple sclerosis (MS). The work, presented this month in the ECTRIMS congress (European Committee for Treatment and Research in Multiple Sclerosis), opens new perspectives in the treatment of children and adolescents suffering from this neurodegenerative disease.
“We realised that, although Natalizumab has no formal indication to be used in children and teenagers, it is very effective in the control of the disease in youngsters”, explains Filipe Paiva. The result of the study TyPed (Tysabri® for the Treatment of Pediatric Multiple Sclerosis) is especially significant bearing in mind that although only 5 to 10 per cent of MS cases start to show symptoms in early ages, there are not many available treatment strategies for children and teenagers. “The classic treatment with injections (subcutaneous or intramuscular) becomes quite complex for such a sensitive population as the paediatric one”, Doctor Paiva adds. “If we use an assertive and efficient treatment with few side effects, it may have a major impact on the long-term functional capacity of these children and adolescents.” In the future, Filipe Paiva intends to continue his research– for now conducted on animal models– in order to find new medicines that may enhance the recovery process of damage caused by multiple sclerosis.
News article: Rui Marques Simões
Translation: Diana Taborda